Home | Contact | Site Map | Imprint | Webmail | 

Rhein Biotech GmbH

Who we are

Rhein Biotech, the European subsidiary of Dynavax Technologies, USA, has over 25 years of experience in biotechnology and is dedicated to the manufacture of biopharmaceuticals.

 

What we do

We have successfully developed production technologies for a wide span of products, including vaccines, cytokines, hormones and industrial enzymes. Seven of our products have been licensed and are available on the global market, including a recombinant Hepatitis B vaccine which is part of national and supranational vaccination programs worldwide. Our technology for Hepatitis B production is also the basis for the investigational adult Hepatitis B vaccine, HEPLISAV™, a lead product candidate of Dynavax Technologies.

 

Our lead product candidate

HEPLISAV™ is a Phase 3 investigational adult hepatitis B vaccine which has demonstrated improved immunogenicity in clinical trials. A Biologics License Application (BLA) and a Marketing Authorization Application (MAA) for HEPLISAV™ are under review by US and European authorities, respectively. In our licensed GMP facility, we are manufacturing the drug substance and performing QC testing for HEPLISAV™.

We know that the work we do has the power to make a change in peoples’ lives! That is what motivates our international team to constantly improve, innovate and pioneer.

 

Contact us

Rhein Biotech GmbH
Dynavax Europe
Eichsfelder Strasse 11
D-40595 Düsseldorf

Phone: +49 (0)211 7 58 45 0
Fax: +49 (0)211 7 58 45 130
E-Mail: info(at)rheinbiotech.de